ConductScience.org, home

Paper40114780

Formulation of Bacteriophage for Inhalation to Treat Multidrug-Resistant Pulmonary Infections.

Pathak V and 2 others. Kona, 2025. Cited by 5 papers, by iCite.

Cite this record

ConductScience Library. Formulation of Bacteriophage for Inhalation to Treat Multidrug-Resistant Pulmonary Infections. Papers, record 40114780. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40114780

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Formulation of Bacteriophage for Inhalation to Treat Multidrug-Resistant Pulmonary Infections.
PubMed
Journal
Kona
PubMed
Year
2025
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
5
iCite
Relative citation ratio, by iCite
1.52, provisional
iCite
Revised in PubMed
2025-03-23
PubMed

Authors3

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Pathak VVaibhav
2Chan HKHak-Kim
3Zhou QTQi Tony

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

Grants2

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
R01 AI146160NIAID NIH HHSUnited StatesR01AI146160PubMed and NIHNIH RePORTER
R01 HL167828NHLBI NIH HHSUnited StatesR01HL167828PubMed and NIHNIH RePORTER

Download CSV of grants

References62

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
133202354Unlocking the next generation of phage therapy: the key is in the receptors.Curr Opin Biotechnol2021https://conductscience.org/library/papers/33202354PubMed
226442188Phage therapy of pulmonary infections.Bacteriophage2015https://conductscience.org/library/papers/26442188PubMed
323360765Unraveling protein stabilization mechanisms: vitrification and water replacement in a glass transition temperature controlled system.Biochim Biophys Acta2013https://conductscience.org/library/papers/23360765PubMed
430763536Phage Therapy: A Renewed Approach to Combat Antibiotic-Resistant Bacteria.Cell Host Microbe2019https://conductscience.org/library/papers/30763536PubMed
525254623Update on the antibiotic resistance crisis.Curr Opin Pharmacol2014https://conductscience.org/library/papers/25254623PubMed
634452123The Influence of Formulation Components and Environmental Humidity on Spray-Dried Phage Powders for Treatment of Respiratory Infections Caused by Acinetobacter baumannii.Pharmaceutics2021https://conductscience.org/library/papers/34452123PubMed
711823954Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare?Clin Infect Dis2002https://conductscience.org/library/papers/11823954PubMed
824950368Instability of bacteriophages in spray-dried trehalose powders is caused by crystallization of the matrix.Int J Pharm2014https://conductscience.org/library/papers/24950368PubMed
936140035Activity of Phage-Lactoferrin Mixture against Multi Drug Resistant Staphylococcus aureus Biofilms.Antibiotics (Basel)2022https://conductscience.org/library/papers/36140035PubMed
1012846264The threat from the pink corner.Ann Med2003https://conductscience.org/library/papers/12846264PubMed
1132440564Inhalable bacteriophage powders: Glass transition temperature and bioactivity stabilization.Bioeng Transl Med2020https://conductscience.org/library/papers/32440564PubMed
1231845128Trileucine and Pullulan Improve Anti-Campylobacter Bacteriophage Stability in Engineered Spray-Dried Microparticles.Ann Biomed Eng2020https://conductscience.org/library/papers/31845128PubMed
1333302377Lactoferrin and Its Derived Peptides: An Alternative for Combating Virulence Mechanisms Developed by Pathogens.Molecules2020https://conductscience.org/library/papers/33302377PubMed
1438247630New Antimicrobial Strategies to Treat Multi-Drug Resistant Infections Caused by Gram-Negatives in Cystic Fibrosis.Antibiotics (Basel)2024https://conductscience.org/library/papers/38247630PubMed
1520196657Bacteriophages can treat and prevent Pseudomonas aeruginosa lung infections.J Infect Dis2010https://conductscience.org/library/papers/20196657PubMed
1627776446Inhaled phage therapy: a promising and challenging approach to treat bacterial respiratory infections.Expert Opin Drug Deliv2017https://conductscience.org/library/papers/27776446PubMed
1722334867Pros and cons of phage therapy.Bacteriophage2011https://conductscience.org/library/papers/22334867PubMed
1829777836Phage therapy against Achromobacter xylosoxidans lung infection in a patient with cystic fibrosis: a case report.Res Microbiol2018https://conductscience.org/library/papers/29777836PubMed
1927130366Evaluation of excipients for enhanced thermal stabilization of a human type 5 adenoviral vector through spray drying.Int J Pharm2016https://conductscience.org/library/papers/27130366PubMed
2038081559Understanding the impact of mannitol on physical stability and aerosolization of spray-dried protein powders for inhalation.Int J Pharm2024https://conductscience.org/library/papers/38081559PubMed

See all 62 referencesDownload CSV of references

Cited by5

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 5 citations.

PMIDTitleJournalYearIn PapersSource
42495612Immunotherapy for tuberculosis: emerging modalities, cross-disciplinary innovations, and roadmaps for drug-resistant disease.Front Immunol2026https://conductscience.org/library/papers/42495612PubMed
40871096Latest Advances in Inhalable Dry Powder Bacteriophage Therapy for Pulmonary Infections.Pharmaceutics2025https://conductscience.org/library/papers/40871096PubMed
40760229Long-term Storage Stability of Inhalable Phage Powder Formulations: A Four-Year Study.AAPS J2025https://conductscience.org/library/papers/40760229PubMed
40426553Virological and Pharmaceutical Properties of Clinically Relevant Phages.Antibiotics (Basel)2025https://conductscience.org/library/papers/40426553PubMed
40250500Powder aerosol formulation of Pseudomonas aeruginosa bacteriophage for pulmonary delivery.Int J Pharm2025https://conductscience.org/library/papers/40250500PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/40114780

GET https://conductscience.org/api/papers/v1/40114780/references?page=2